Abstract
We successfully treated 3 consecutive patients who had nonneutropenic rhinocerebral zygomycosis, by use of subcutaneous granulocyte-macrophage colony-stimulating factor therapy combined with traditional surgical and medical treatment. All patients are currently free of disease. Granulocyte-macrophage colony-stimulating factor should be considered as adjuvant therapy for rhinocerebral zygomycosis; however, optimum dose and length of therapy are unknown.
MeSH terms
-
Adjuvants, Pharmaceutic / administration & dosage
-
Adjuvants, Pharmaceutic / therapeutic use*
-
Aged
-
Amphotericin B / therapeutic use
-
Drug Combinations
-
Female
-
Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
-
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
-
Humans
-
Male
-
Middle Aged
-
Mucormycosis / drug therapy*
-
Mucormycosis / pathology
-
Mucormycosis / surgery
-
Phosphatidylcholines / therapeutic use
-
Phosphatidylglycerols / therapeutic use
-
Rhizopus / drug effects*
-
Rhizopus / isolation & purification
-
Treatment Outcome
Substances
-
Adjuvants, Pharmaceutic
-
Drug Combinations
-
Phosphatidylcholines
-
Phosphatidylglycerols
-
liposomal amphotericin B
-
Amphotericin B
-
Granulocyte-Macrophage Colony-Stimulating Factor